Navigation Links
FDA Grants Orphan Drug Status To Eisai's Lenvatinib
Date:2/14/2013

which is to help address unmet medical needs and to increase the benefits health care provides to patients and their families. Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, biologic and supportive care agents for cancer across multiple indications.

Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Media InquiriesInvestor InquiriesLaurie Landau

Alex Scott Eisai Inc.

Eisai
'/>"/>

SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Calif., Oct 21 MAP Pharmaceuticals, Inc. (Nasdaq: ... of Thomas P. McCracken as Vice President, Intellectual ... property program in support of the potential commercialization ... inhaled migraine therapy, and other product opportunities. ...
... (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer ... Backer, Ph.D., to the newly-created position of senior vice ... all aspects of chemistry, manufacturing and controls (CMC) in ... pipeline products. "We are extremely pleased to ...
Cached Medicine Technology:MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 2MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property 3Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations 2
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
(Date:4/22/2014)... rabbits, Johns Hopkins scientists have found a way to ... the development of atherosclerosis, the main cause of heart ... among humans. The condition develops when fat builds inside ... and hardened, greatly reducing their ability to feed oxygen-rich ... In a series of experiments, described April 7 in ...
(Date:4/22/2014)... news release is available in German . ... are important intracellular signaling molecules, but their mode of ... aspects of cellular function and behavior, while at high ... membranes and DNA. To analyze how redox signaling unfolds ... optical microscopy technique has been developed jointly by the ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... all seem to know who we say is neurotic and ... unable to act but simply doesn,t want to., ... of nearly 4,000 college students in 19 countries has uncovered ... and moving forward with life. Turns out that when they ... don,t like it as much as non-neurotics. Therefore persuasive communications ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2
... novel pancreatic cancer vaccine shows promise in improving survival when ... University Hospitals Case Medical Center,s Seidman Cancer Center and Case ... was presented today (embargoed 11:00 am ET) at the Annual ... part of Digestive Disease Week in San Diego. ...
... thousands of psychiatrists attend their field,s largest annual meeting ... drug treatments report overwhelmingly on positive results. ... the Journal of Clinical Psychopharmacology by two ... University, who analyzed the presentations given at two recent ...
... The national gastroenterology societies have issued a new document ... Sedation Curriculum for Gastrointestinal Endoscopy (MSCGE) grew out ... to the training of procedure sedation. The document is ... of Gastroenterology , GIE:Gastrointestinal Endoscopy , Hepatology ...
... The Food and Drug Administration has approved a new ... disorders. The test, or assay, was developed by an expert ... Lawrence Schwartz, M.D., Ph.D., chair of the Division of ... Professor of Medicine at VCU, has spent more than 30 ...
... Lies Van Nieuwenhove, researcher at the Antwerp Institute of ... the sleeping sickness parasite. They can be used in ... dangerous parasites. Each year many thousands of ... parasite, a trypanosome, which is transmitted by the bite ...
... TUESDAY, May 22 (HealthDay News) -- Fear of spiders, a ... therapy session, according to a small new study. People ... hold a tarantula after a two- or three-hour therapy session, ... six months, the Northwestern University researchers reported. The lasting ...
Cached Medicine News:Health News:Researchers present new findings for novel pancreatic cancer vaccine 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 3Health News:Gastroenterology Societies issue sedation curriculum for gastrointestinal endoscopy 2Health News:FDA clears test developed in partnership with VCU researcher 2Health News:Better tests for sleeping sickness 2Health News:Spider-Phobes May Get Quick Relief 2
... Vibratome Semi-Automatic Tissue Sectioning System has maintained ... sectioning system. Researchers from around the globe ... for their fresh and fresh fixed tissue ... With the Vibratome Automatic Tissue Sectioning ...
... 1500 Sectioning System provides a versatile means ... plant tissues. The 1500 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effect ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... The NEW Vibratome 3000 Plus Sectioning ... fresh or fixed, animal, or plant tissues. ... principle which allows sectioning without freezing or ... alteration of morphology, the destruction of enzyme ...
Medicine Products: